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pMell7 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and
HMB-50 and by anti-melanoma CTL
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Summary Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gplOO and
demonstrated that gplOO is recognised by three different monoclonal antibodies (MAbs) used to diagnose
malignant melanoma. In addition, we showed that tumour-infiltrating lymphocytes (TIL 1200) from a
melanoma patient reacted specifically with cells transfected with the gplOO cDNA. Molecular characterisation
of the gplOO cDNA revealed that the gplOO antigen is highly homologous, but not identical, to another
melanocyte-specific protein, pMell7. Here, we report that cells transfected with pMel17 cDNA also react with
all three MAbs used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50. Moreover, pMell7
transfectants are specifically lysed by TIL1200. These data demonstrate that antigenic processing of both gplOO
and pMell7 give rise to peptides seen by anti-melanoma cytotoxic T lymphocytes (CTL) and are therefore
potential targets for immunotherapy of malignant melanoma.
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Melanoma is a neoplasm that originates from melanocytes,
pigment-producing cells in the skin. Melanoma is a relatively
immunogenic tumour, as demonstrated by the presence of
both cytotoxic T lymphocytes (CTLs) and antibodies (Mattes
et al., 1983; Knuth et al., 1992) in melanoma patients that
react with melanoma tumour cells. The availability of
antibodies and CTLs with anti-melanoma reactivity allowed
the identification of several tumour-associated antigens.
These include tumour-specific antigens and melanocyte
differentiation antigens that are expressed by melanoma
tumour cells as well as by normal melanocytes and retina
(van der Bruggen et al., 1991; Brichard et al., 1993;
Vijayasaradhi et al., 1990; Bakker et al., 1994; Kawakami
et al., 1994a,b; Coulie et al., 1994; Gaugler et al., 1994 and
Wang et al., 1995). Identification of the antigens recognised
by anti-tumour CTL is important for understanding the
molecular basis of tumour recognition by T cells and may
lead to the development of new immunotherapeutical
strategies to treat cancer patients.
Recently, we cloned the cDNA encoding the melanocyte
differentiation antigen gplOO and demonstrated that it is
recognised by three different MAbs used to diagnose
malignant melanoma, NKI-beteb, HMB-50 and HMB-45
(Adema et al., 1993, 1994). In addition, we demonstrated that
gplOO is recognised by a tumour-infiltrating T-cell line (TIL
1200), isolated from a melanoma patient (Bakker et al.,
1994). Molecular characterisation of the cDNA encoding
gplOO revealed that it is a type I transmembrane glycoprotein
of 641 amino acids highly homologous to another
melanocyte-specific protein, pMell7 (Adema et al., 1994;
Kwon et al., 1991). Nucleotide sequence analysis of genomic
DNA indicated that the transcripts corresponding to gplOO
and pMell7 cDNAs originate from a single gene via
alternative splicing. The difference between gplOO and
pMell7 consists of a stretch of seven amino acids in the
carboxy terminal part of pMell7 (position 567; Adema et al.,
1994) that is absent in gplOO. In all normal and malignant
melanocytic cells expressing the gplOO/pMell7 gene, gplOO
and pMell7 mRNAs are expressed simultaneously.
Here, we demonstrate that pMell7, like gplOO, is
recognised by all three MAbs used to diagnose malignant
melanoma and is properly processed and presented to anti-
melanoma tumour-infiltrating lymphocytes.
Materials and methods
Cells and monoclonal antibodies
Culturing of the melanoma cell lines MEWO, BLM and of
COS-7 cells has been described previously (Adema et al.,
1993; 1994). TIL 1200 was generated from a metastatic
melanoma and cultured with 1000 U ml-' interleukin-2 (IL-
2) (Cetus Corp., Emeryville, CA, USA) as described
previously (Kawakami et al., 1992). NKI-beteb and HMB-
50 have been described previously (Vennegoor et al., 1988;
Vogel and Esclamado, 1988). HMB-45 was purchased from
Enzo Biochem.
Molecular cloning and nucleotide sequence analysis
Using a reverse transcriptase-polymerase chain reaction
(PCR) (GeneAmp kit, Perkin elmer, the Netherlands)
approach with 5'-ctgcatggagatcttcatcg-3' as the 5' primer
and 5'-ttctgtgagctccaggaaaatcacagcat-3' as the 3' primer we
isolated the 3' part of pMell7 cDNA from total RNA
isolated from the melanoma cell line MEWO. The PCR
product was used to replace the 3' part of the gplOO cDNA
as present in pSVLgp OO+ (Adema et al., 1994) using BglII
and the newly created Sacd site in the 3' primer (underlined).
The resulting construct, pSVLpMell7, was sequenced by the
dideoxy-nucleotide sequencing method using T7 DNA
polymerase (Pharmacia, Woerden, The Netherlands).
pCMVneopMell7 was constructed by cloning the complete
pMell7 cDNA from pSVLpMell7 as a blunt-ended XbaI-
SacI fragment in the blunt-ended BamHI site of PCMVneo
(Bakker et al., 1994).
Transfections and immunostaining
Transient expression of DNA constructs in COS-7 cells was
performed using 40 Mg ml-' lipofectin reagent (BRL,
Gaithersburg, MD, USA) and 7.5 ,ug of DNA. BLM cells
were transfected with 20 jug of pCMVneopMell7 DNA using
calcium phosphate transfection systems (BRL, Gaithersburg,
MD, USA) and stable clones were isolated by G418 selection
(1 mg ml-') as previously described (Bakker et al., 1994).
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December 1995Transfected cells were prepared for immunofluorescence
using FITC-conjugated GAM-IgG-F(ab')2 (Zymed, San
Francisco, CA, USA) as described previously (Adema et
al., 1993) and examined using confocal laser scanning
microscope at 488 nm (Biorad MRC 600).
Metabolic labelling and immunoprecipitations
Immunoprecipitation experiments were performed on
metabolically labelled (L-[35S]methionine/cysteine; Amer-
sham) cells as described by Vennegoor et al. (1988) using
either NKI-beteb or HMB-50 covalently linked to protein
A-CL 4B sepharose beads (Pharmacia, Woerden, The
Netherlands). Immunoprecipitates were analysed under
reducing conditions by SDS-PAGE using 5-17.5%
gradient gels. The relative molecular weight of the proteins
was determined using co-electrophorised, prestained markers
(BRL, Gaithersburg, MD, USA). Gels were treated with
1 M sodium salicylate (pH 5.4) before autoradiography
(Kodak XAR).
Chromium-release assay
Chromium release assays were performed as described
previously (Bakker et al., 1994). Briefly, 106 target cells
were incubated with 100 pCi [5'Cr]sodium chromate (Amer-
sham, Bucks, UK) for 1 h. Various amounts of effector cells
were then added to 2 x 103 target cells in triplicate wells of U-
bottomed microtitre plates (Costar, Badhoevedorp, The
Netherlands) in a final volume of 150 ,l. After 5 h of
incubation part of the supernatant was harvested and its
radioactive content was measured.
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Results
The gplOO/pMell7 gene encodes both gplOO and pMell7
mRNA as a consequence of alternative RNA processing. The
pMell7 mRNA encodes a stretch of seven amino acids not
encoded by the gplOO mRNA (Figure 1). To investigate the
immunological properties of pMell7 we constructed a
pMell7 cDNA. Using an RT-PCR approach we first cloned
the 3' part of the pMell7 cDNA encoding the carboxy
terminal part of pMell7, including the additional seven
amino acids absent in gplOO. Nucleotide sequence analysis of
the 3' part confirmed the presence of the nucleotide sequence
PMEL1 7
GP100
LLTGQEAGL
ILLTGQEAGL
GILLTGQEA
IMPVPGILL
QLIMPVPGIL
QLIMPVPGI
AVVSTQLIMPVPGILLTGQEAGLGQVPL
AVVSTQLIMPGQEAGLGQVPL
QLIMPGQEA
LIMPGQEAGL
IMPGQEAGL
Figure 1 Peptides unique in pMell7 and gplOO that fit the HLA-
A2.1 binding motifs [Falk et al. (1991), Drijfhout et al. (1995)].
The pMell7 specific amino acids are indicated in bold.
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Figure 2 MAbs NKI-beteb, HMB-45 and HMB-50 recognise pMell7. BLM cells transfected with PSVLpMell7 were analysed for
reactivity with NKI-beteb (a), HMB-45 (b), HMB-50 (c) or the secondary antibody (d) respectively. Indirect immunofluorescence
[FITC-conjugated GAM-IgG-F(ab')2] was examined by confocal laser scanning microscopy. Magnification 60 x.pMell7 is recognised by anti-melanoma CTL and MAbs
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encoding the pMell7-specific amino acids. In addition, we
found pMell7 cDNAs containing either a thymidine (as in
the gplOO cDNA; Adema et al., 1994) or a cytosine at
position 1998. This nucleotide change does not result in an
amino acid substitution. The finding that the same nucleotide
difference was found in a gplOO cDNA clone isolated from
the same cell line, indicates that this particular cell line
contains two different alleles of the gplOO/pMell7 gene.
Subsequently, we created a full length pMell7 cDNA by
exchanging the 3' part of the gplOO cDNA with the 3' part of
pMell7 cDNA.
To investigate whether the difference between gplOO and
pMell7 affects recognition by the anti-gplOO MAbs NKI-
beteb, HMB-45 and HMB-50, we transfected the cDNA
encoding pMell7 into the gplOO/pMell7 negative melanoma
cell line BLM. As shown in Figure 2, expression of the
pMell7 cDNA resulted in immunoreactivity with all three
MAbs. The typical speckled staining pattern of the pMell7
transfectants was identical to that previously observed for
gplOO, suggesting that pMell7, like gplOO, localises in
melanosomes. Immunoreactivity with all three MAbs was
also observed when pMell7 cDNA was transiently expressed
in non-melanocytic COS-7 cells (data not shown). We also
analysed the pMell7 protein detected by MAbs NKI-beteb or
HMB-50 in COS-7 cells transfected with the pMell7 cDNA
using immunoprecipitations reactions. As shown in Figure 3,
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Figure 3 The pMell7 protein is recognised by NKI-beteb and
HMB-50 in extracts from pSVLpMell7 transfected COS-7 cells.
MEWO cells (MEWO) and COS-7 cells transfected with either
pSVLpMell7 (pMell7), pSVLgplOO (gplOO) or with a construct
encoding the gplOO cDNA in the non-coding orientation (Mock)
were metabolically labelled and subjected to immunoprecipita-
tions using NKI-beteb (NKI), HMB-50 (50) or normal mouse
serum (NMS) as indicated above each lane. Immunoprecipitated
proteins were analysed under reducing conditions by SDS-PAGE
(linear gradient of 5-17% acrylamide) and visualised by
autoradiography. The position and size (kDa) or prestained
molecular weight markers are indicated.
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NKI-beteb and HMB-50 both specifically detect proteins of
approximately 100 kDa (95-110 kDa) in extracts of
metabolically labelled COS-7 cells transfected with the
pMell7 cDNA. The pMell7 protein co-migrates with the
gplOO protein immunoprecipitated from COS-7 cells trans-
fected with gplOO cDNA as well as with the proteins
immunoprecipitated from MEWO melanoma cells. The
slight difference in mobility between transfected COS-7 cells
and MEWO melanoma cells, which express both gplOO and
pMell7 endogenously, has previously been shown to be due
to differential glycosylation (Adema et al., 1994). Collectively,
these data demonstrate that the difference between gplOO and
pMell7 does not affect recognition by either of the MAbs
used to diagnose malignant melanoma, NKI-beteb, HMB-50
and HMB-45. The data describing the specificity of these
MAbs for cells of the melanocytic lineage can therefore be
extrapolated to the expression of pMell7.
Previously, we showed that gplOO is recognised by
tumour-infiltrating lymphocytes, (TIL)1200, isolated from a
melanoma patient in an HLA-A2.1 restricted manner
(Bakker et al., 1994). To investigate whether the pMell7
antigen also gives rise to peptide epitopes that gain access to
the MHC class I antigen presentation pathway, we
determined the cytolytic activity of TIL 1200 against HLA-
A2.1 +BLM cells transfected with the pMell7 cDNA. As
demonstrated in Figure 4, the pMel17 transfectants were
efficiently lysed by TIL 1200. No specific lysis was observed
using the parental, untransfected BLM cells or BLM cells
transfected with the expression vector without an insert (not
shown). These data demonstrate that peptide epitope(s)
recognised by TIL 1200 are properly processed from the
pMell7 protein and presented in the context of HLA-A2.1.
Two gplOO-derived peptides (corresponding to the amino
acids at positions 154-162 and 457-466) have been
identified that are recognised by TIL 1200 (Bakker et al.,
1995; Kawakami et al., 1995). These peptides are located in
the common part between gplOO and pMell7. Since TIL 1200
is an oligoclonal, CD8+ T-cell line expressing a restricted
number of T-cell receptors (Shilyanski et al., 1994), it is most
likely that either one or both the aforementioned immuno-
genic peptides are responsible for the observed lysis of the
pMell7 and gplOO transfectants.
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Figure 4 Lysis of HLA-A2.1 +pMell7 transfectants by TIL1200.
BLM cells transfected with pCMVneopMell7, pCMVneogplOO,
the parental BLM cells and the gplOO/pMell7 positive Mel624
cells were tested for sensitivity to lysis by TIL1200. One
representative experiment with the stable pMell7 transfected
clone ABI is shown. -El , BLM; ---, Mel624; -*-BLM
gplOO H2.3; -A-, BLM pMell7 ABI.
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1 MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYP
51 EWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDG
101 QVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFV
151 YVWKTWGOYWOVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPL
201 AHSSSAFTITDOVPFSVSVSQLRALDGGNKHFLRNQPLTFALQLHDPSGY
251 LAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTS
301 CGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTS
351 VQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGM
401 TPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESI
451 TGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQGIESAEILQ
501 AVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPAC
551 QLVLHQILKGGSGTYCLNVSLADTNSLAWSTQLIMPVPGILL TUQEAG
600 LGQVPLIVGILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPR
650 IFCSCPIGENSPLLSGQQV
Figure 5 Amino acid sequence of the pMell7 antigen (including signal peptide) and location of the peptide epitopes. The peptide
epitopes as recognised in the gplOO antigen are underlined [Bakker et al. (1995), Kawakami et al. (1995), Cox et al. (1994)]; the
amino acids uniquely present in pMell7 are in italic capitals.
Discussion
The data described in this report demonstrate that pMell7,
like gplOO, is recognised by three MAbs frequently used to
diagnose melanoma. In addition, we demonstrate that cells
transfected with pMell7 cDNA are effectively lysed by anti-
melanoma T cells.
Because of the exclusive reactivity of MAbs NKI-beteb,
HMB-45 and HMB-50 with cells of the melanocyte lineage,
they are frequently used to diagnose malignant melanoma
(Ruiter, 1990). The finding that not only gplOO but also
pMell7 reacts with these antibodies emphasises the specific
expression of both gplOO and pMell7 in cells of the
melanocyte lineage. The identical staining pattern observed
with the MAbs in gplOO and pMell7 transfectants further
indicates that, like gplOO, pMell7 is also present in
melanosomes, which is in line with their proposed role in
the process of pigmentation (Kwon et al., 1991). Whether
there exists a functional difference between gplOO and
pMell7 remains to be determined.
The relative immunogenicity of melanoma tumours has
long been recognised. Both cytotoxic T cells and MAbs have
been identified that specifically recognise melanoma tumour
cells. So far, a number of the antigens recognised have been
characterised in detail. They include the tumour-specific
proteins, MAGE-1 (van der Bruggen et al., 1991) and
MAGE-3 (Gaugler et al., 1994), which are expressed in
different types of tumour cells and in testis. In addition, the
melanocyte differentiation antigens tyrosinase, gplOO, Melan-
A/MART-1 and gp75 (Brichard et al., 1993; Bakker et al.,
1994; Kawakami et al., 1994a,b; Coulie et al., 1994; Wang et
al., 1995) that are expressed in normal and malignant
melanocytes as well as in retina have been identified as
targets for anti-melanoma CTLs. Potentially, these antigens
are targets for specific immunotherapy.
TIL1200 was isolated from a melanoma metastasis and
was shown to recognise the melanocyte differentiation
antigen gplOO. Interestingly, reinfusion of in vitro expanded
TIL1200 together with IL-2 in the autologous patient resulted
in objective tumour regression (Kawakami et al., 1994b,
1995). Here we demonstrate that TIL1200 not only recognises
the gplOO antigen, but also the pMell7 antigen that is
encoded by an mRNA species derived from the same gene via
alternative splicing. Since we have previously shown that
melanoma cells express gplOO and pMell7 mRNA simulta-
neously, both proteins contribute to the total amount of
immunogenic peptides presented in the context of HLA-A2.1
that are recognised by TIL1200. This finding is also
consistent with the recent mapping of two peptide epitopes
(corresponding to the amino acids at positions, 154- 162 and
457-466) recognised by TIL1200 in the common part of
gplOO and pMell7 (Bakker et al., 1995; Kawakami et al.,
1995 and Figure 5). Although it has been observed that
sequence context can affect processing and/or presentation of
T-cell epitopes (Eisenlohr et al., 1992; Del Val et al., 1991),
this does not seem to be the case for pMell7 and gplOO. The
fact that TIL1200 is an oligoclonal, CD8+ T-cell line
expressing a restricted number of T-cell receptors (Shilyan-
ski et al., 1994), implies that either one or both these epitopes
are properly processed from the pMell7 antigen and
presented by HLA-A2.1. Attempts to further investigate the
recognition of the pMell7 epitopes using cloned TIL have
not been successful.
Besides TIL1200, other CTL-recognising distinct epitopes
encoded by the gplOO/pMell7 have recently been charac-
terised (Cox et al., 1994; Kawakami et al., 1995). A total of
five distinct peptides have now been identified (Figure 5), all
of which are present in both gplOO and pMell7, and are
presented by the same restriction element, HLA-A2.1.
Examination of the additional amino acid sequence presentpMI17 is recognised by meanona CTL aid A
__ kGJ Adema et al
1048
in pMell7 revealed that six peptides (including 9- and 10-
mers) bearing the HLA-A2.1 binding motif are uniquely
present in pMell7, whereas three peptides are specifically
present in gplOO (Figure 1). HLA-A2.1 stabilisation
experiments revealed that two of the pMell7-specific
peptides listed in Figure 1 bind to HLA-A2.1 (ABHB and
GJA unpublished observation). When analysing immunor-
eactivity against the products of the gplOO/pMell7 gene, one
should therefore include both gplOO and pMell7.
In conclusion, the data presented in this report demon-
strate that pMell7 is recognised by three different MAbs used
to diagnose melanoma and functions as a target for anti-
melanoma CTLs.'
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